11月17日,生物制药公司诺和诺德宣布,全球首个且目前唯一用于长期体重管理的GLP-1RA(胰高糖素样肽-1受体激动剂)周制剂诺和盈(用于长期体重管理的司美格鲁肽注射液)正式在中国上市。 据悉,诺和盈能实现平均约17%的体重降幅,其减重效果至少可以持续两年。一项临床研究结果显示,诺和盈带来的体重减轻以脂肪组织的减少为主。此外,诺和盈为患者带来超越减重的多重健康获益,包括但不限于减少腰围、降低内脏...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.